天眼查App显示，近日，益阳市大通湖区群富湘玉竹种植有限公司成立，法定代表人为刘唐山，注册资 本500万人民币，经营范围为许可项目：农作物种子经营;农药批发;农药零售;农药生产;农药登记试验 （依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以批准文件或许可证件为 准）一般项目：中草药种植;中草药收购;卫生用杀虫剂销售;技术服务、技术开发、技术咨询、技术交 流、技术转让、技术推广;农业专业及辅助性活动;农作物病虫害防治服务（除依法须经批准的项目外， 自主开展法律法规未禁止、未限制的经营活动）。 ...

Core Viewpoint - The article highlights the successful transformation of Kongque Village in Ningxia, focusing on the cultivation of traditional Chinese medicinal herbs, particularly Atractylodes macrocephala and Saposhnikovia divaricata, which are expected to bring significant economic benefits and support rural revitalization efforts [1][2]. Group 1: Economic Potential - The medicinal herb market is characterized by high demand and limited supply, with suitable cultivation areas primarily in Gansu, Anhui, and Ningxia [1]. - The cooperative has expanded its cultivation area from 7 acres in 2024 to 120 acres, with 100 acres dedicated to Atractylodes macrocephala and approximately 10 acres each for Saposhnikovia divaricata and Salvia miltiorrhiza [1][2]. Group 2: Employment and Community Impact - The cultivation project has created local employment opportunities, averaging 45 workers daily since planting began on March 23, allowing villagers to earn income close to home [2]. - The dual benefit of stable land transfer income and additional earnings from labor has resulted in a win-win situation for the villagers [2]. Group 3: Future Plans and Growth - The cooperative aims to guide more villagers into medicinal herb cultivation, planning to increase Atractylodes macrocephala planting to 300 acres within three years, with unified procurement, processing, and sales [2]. - The anticipated yield for Atractylodes macrocephala is between 3,000 to 3,500 pounds per acre, with expected average earnings exceeding 12,000 yuan per acre, significantly surpassing traditional crop returns [2].

Industry Overview - Chinese herbal medicine is a unique drug used in traditional Chinese medicine for disease prevention and treatment, encompassing both herbal medicine and traditional Chinese drugs [1][5] - The market size of Chinese herbal medicine planting in China is projected to grow from 156.3 billion yuan in 2019 to 295.68 billion yuan in 2024, with a year-on-year growth rate of 30.2% [9] - The planting area for Chinese herbal medicine has increased from 52.5 million mu in 2019 to 59.56 million mu in 2024, reflecting a year-on-year growth rate of 5.87% [5][9] Industry Chain - The upstream of the industry chain includes the planting of Chinese herbal medicine, breeding of medicinal animals, and collection of raw materials, with key players such as Baiyunshan, Kangmei Pharmaceutical, and Yunnan Baiyao [2] - The midstream involves the processing and manufacturing of Chinese herbal products, including traditional Chinese medicine and herbal pieces, with companies like Kangmei Pharmaceutical and Huaren Sanjiu leading this segment [2] - The downstream focuses on the distribution and sales of Chinese herbal products through traditional pharmacies and e-commerce platforms [2] Market Dynamics - The demand for Chinese herbal medicine is increasing due to factors such as industrialization, urbanization, and an aging population, alongside supportive government policies [9] - The recognition of traditional Chinese medicine in international markets is also on the rise, contributing to the industry's rapid growth [9] Competitive Landscape - The competitive landscape of the Chinese herbal medicine planting industry is tiered based on registered capital, with the first tier exceeding 1 billion yuan, including companies like Yunnan Baiyao and Kunming Pharmaceutical [11][13] - The second tier has registered capital between 500 million to 1 billion yuan, featuring companies like Yibai Pharmaceutical and Dong'e Ejiao [11][13] - The third tier consists of companies with registered capital below 500 million yuan, such as Foci Pharmaceutical and Zhendong Pharmaceutical [11][13] Development Trends - The establishment of geographical indication and ecological planting models is accelerating the construction of authentic medicinal material protection zones [17] - The standardization of seeds and seedlings is expected to overcome industry bottlenecks, with significant improvements in the coverage of quality seeds [17] - International certifications such as EU organic certification and US NOP standards are becoming essential for export enterprises, enhancing the competitiveness of Chinese herbal products in global markets [18]